SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

BACKGROUND: Glioblastoma is one of the most devastating cancer worldwide based on its locally aggressive behavior and because it cannot be cured by current therapies. Defects in alternative splicing process are frequent in cancer. Recently, we demonstrated that dysregulation of the spliceosome is di...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuentes-Fayos, Antonio C., Pérez-Gómez, Jesús M., E. G-García, Miguel, Jiménez-Vacas, Juan M., Blanco-Acevedo, Cristóbal, Sánchez-Sánchez, Rafael, Solivera, Juan, Breunig, Joshua J., Gahete, Manuel D., Castaño, Justo P., Luque, Raúl M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793262/
https://www.ncbi.nlm.nih.gov/pubmed/35086552
http://dx.doi.org/10.1186/s13046-022-02241-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793262/
https://www.ncbi.nlm.nih.gov/pubmed/35086552
http://dx.doi.org/10.1186/s13046-022-02241-4

Ejemplares similares